Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice

Edit B. Olasz, Jooyoung Roh, Carole L. Yee, Ken Arita, Masashi Akiyama, Hiroshi Shimizu, Jonathan C. Vogel, Kim B. Yancey

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one type of epidermolysis bullosa (OMIM #226650). A keratin 14 promoter construct was used to produce transgenic (Tg) mice appropriately expressing human BPAG2 (hBPAG2) in murine epidermal basement membrane (BM). Grafts of Tg skin placed on gender-matched, syngeneic wild type (Wt) or major histocompatibility complex I (MHC I)-/- mice elicited IgG that bound human epidermal BM and BPAG2. Production of such IgG in grafted mice was prompt (detectable within 16±2 days), robust (titer ≥1,280), durable (present ≥380 days), and correlated with the involution and loss of Tg skin grafts. MHC II-/- mice grafted with Tg skin did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4+ T cell interactions were crucial for these responses. Tg skin grafts on Wt mice developed neutrophil-rich infiltrates, dermal edema, subepidermal blisters, and deposits of immunoreactants in epidermal BM. This model shows fidelity to alterations seen in patients with BP, has relevance to immune responses that may arise in patients with epidermolysis bullosa following BPAG2 gene replacement, and can be used to identify interventions that may block production of IgG against proteins in epidermal BM.

Original languageEnglish (US)
Pages (from-to)2807-2817
Number of pages11
JournalJournal of Investigative Dermatology
Volume127
Issue number12
DOIs
StatePublished - Dec 2007

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this